CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 34,238 enrolled
Drug / intervention
Semaglutidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06351748
NCT06351748N/ACompleted
CompareCT.gov

Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

Novo Nordisk A/S·observational·Posted Apr 8, 2024·Updated Apr 16, 2025

In Brief

An observational study evaluating Semaglutide for Diabetes Mellitus, Type 2. Completed, enrolled 34,238 participants across 1 site.

Detailed Summary

This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China\] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedApr 8, 2024
Enrollment StartJan 2, 2024
Primary CompletionMar 29, 2024
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 2.2 years ago

Interventions

Semaglutidedrug

Participants received semaglutide OW according to local label and to routine clinical practice at the discretion of the treating physician.